Key Findings
Keymed Biosciences reported its financial results and business updates for the first half of 2026, highlighting significant progress for its BCMA x CD3 bispecific antibody, CM336, which is advancing in a Phase II clinical trial for relapsed/refractory light chain amyloidosis. CM336 received Breakthrough Therapy Designation (BTD) in May 2026, recognizing its therapeutic potential. Additionally, Ouro Medicines, Keymed’s partner for CM336, was acquired by Gilead Sciences, resulting in Keymed receiving an upfront payment of $257 million and eligibility for up to approximately $70 million in milestone payments. The company also confirmed ongoing international multi-center Phase I/II clinical trials for its CD20 x CD3 bispecific antibody, CM355/PRO-203.
Technical/Clinical Details
CM336 (BCMA x CD3 Bispecific Antibody): This antibody is being developed to treat light chain amyloidosis (AL amyloidosis), a rare blood disorder characterized by the abnormal deposition of immunoglobulin light chains. There is a critical need for new treatment options for patients whose disease is refractory to existing therapies. CM336 targets both B-cell maturation antigen (BCMA), expressed on multiple myeloma cells and plasma cells responsible for light chain production, and CD3 on T cells, redirecting T cells to eliminate the abnormal cells. The ongoing Phase II trial, coupled with the early BTD, signifies high expectations for its clinical superiority. The acquisition of Ouro Medicines by Gilead reflects strong validation of CM336’s technology and global potential.
CM355/PRO-203 (CD20 x CD3 Bispecific Antibody): This bispecific antibody is currently in an international multi-center Phase I/II clinical trial for patients with systemic sclerosis (SSc). The first patient was dosed in June 2026. CM355 targets CD20 on B cells and CD3 on T cells, functioning as an immunotherapy to modulate B-cell activity, which is implicated in the pathogenesis of autoimmune diseases like SSc. The aim is to improve the clinical manifestations of SSc by controlling aberrant B-cell activation.
Background & Context
Keymed Biosciences is a clinical-stage Chinese biotechnology company dedicated to developing innovative bispecific antibodies and other biologics. The company focuses on areas with high unmet medical needs, such as rare diseases like light chain amyloidosis and challenging autoimmune conditions like systemic sclerosis. The attainment of BTD and the acquisition of a partner company by a major pharmaceutical firm validate Keymed’s technological platform and pipeline value, indicating the increasing global prominence of Chinese biopharmaceutical innovation.
Strategic Significance & Outlook
The successful progression of CM336 in its Phase II trial holds the potential to transform the treatment landscape for light chain amyloidosis. Through the partnership with Gilead, the development of CM336 is expected to accelerate, leading to broader patient access. The clinical development of CM355 is also progressing well, potentially offering a new therapeutic option for patients with systemic sclerosis. Keymed Biosciences is anticipated to continue leveraging its bispecific antibody platform to create innovative therapies across diverse disease areas, solidifying its position in the global biopharmaceutical market and bringing much-needed treatments to patients worldwide.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments